OrganonOGN +0.22%73 FCF Margin % is 12.19% as of Mar. 2026, which is 37% below its 10-year median of 19.38. GuruFocus rates OGN with a GF Score™ of 73/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 9 warning signs investors should review. Among 958 Drug Manufacturers companies, Organon ranks better than 69.31% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Organon's Free Cash Flow for the
three
months ended in Mar. 2026 was $178 Mil. Organon's Revenue for the
three
months ended in Mar. 2026 was $1,460 Mil. Therefore, Organon's FCF Margin % for the quarter that ended in Mar. 2026 was 12.19%.
The historical rank and industry rank for Organon's FCF Margin % or its related term are showing as below:
OGN'
s FCF Margin % Range Over the Past 10 Years
Min: 6.18 Med: 19.38 Max: 36.68
Current: 9.48
During the past 8 years, the highest FCF Margin % of Organon was 36.68%. The lowest was 6.18%. And the median was 19.38%.
OGN's FCF Margin % is ranked better than 69.31% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs OGN: 9.48
Organon FCF Margin % Related Terms
Organon FCF Margin % Historical Data
* Premium members only.
The historical data trend for Organon's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Organon's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Organon's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon (OGN) has a FCF Margin % of 12.19% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Organon and its competitors. This is 37% below median its historical median of 19.38. Over the past decade, Organon's FCF Margin % has ranged from 6.18 to 36.68. According to the industry distribution chart, Organon ranks #294 out of 958 companies in the Drug Manufacturers industry, placing it in the top 30.7%.
Is Organon's FCF Margin % too high?
Organon's current FCF Margin % of 12.19% is 37% below median its 10-year median of 19.38. Over the past 10 years, this metric has ranged from a low of 6.18 to a high of 36.68. The Drug Manufacturers industry median FCF Margin % is 2.51. Organon's value of 12.19% is 385.7% above this industry median. Based on the distribution chart, Organon ranks #294 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organon has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's FCF Margin % compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #294 out of 958 companies for FCF Margin %. This puts Organon in the upper half of its industry. The industry median FCF Margin % is 2.51. Organon's value of 12.19% is 385.7% above this benchmark. Historically, Organon's own FCF Margin % has ranged from 6.18 to 36.68 over the past decade. While the company's 10-year median is 19.38 vs. the industry median of 2.51, Organon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organon's current FCF Margin % of 12.19% is 385.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current FCF Margin % is 12.19%, which is 37% below median its own 10-year median of 19.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.48 — trading 7.4% below its estimated fair value. The current FCF Margin % is 12.19%, which is 37% below median its 10-year median of 19.38 and 385.7% above the Drug Manufacturers industry median of 2.51. Organon's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Organon (OGN), the current FCF Margin % is 12.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.48 is trading 7.4% below its estimated GF Value™ of $14.55.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
FCF Margin %: 12.19% (37% below median its 10-year median of 19.38)
GF Value™: $14.55 vs. price of $13.48 (7.4% below fair value)
Industry Position: 385.7% above the Drug Manufacturers median (#294 of 958)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
73GF Score
Get the complete analysis for OGN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
